RNAZ +25% Surges on High Volume, Eyes $12.38 Resistance
$TransCode Therapeutics Inc.(RNAZ)$ TransCode Therapeutics, Inc. (RNAZ) Soars +25.03%: Micro-Cap Biotech Surges on High Volume, Targets $12.38 Resistance Latest Close Data Closed at $12.34 on 2026-01-26, up +25.03% from prior close of $9.87. The stock is trading significantly below its 52-week high of $468.44. Core Market Drivers A surge in small-order buying drove the day's massive 24.62% intraday swing. The company, focused on RNA-based cancer therapeutics, remains in a pre-revenue, high-burn development stage. No specific news was cited for the move, indicating potential speculative or technical-driven activity. Technical Analysis Volume was extremely high at 6.21x the average, confirming the breakout move. The MACD (DIF: 0.544, DEA: 0.114, MAC
$TransCode Therapeutics Inc.(RNAZ)$ Guys the offering aamt is 8 mill DOLLARS at .51 cents, this equates to 15.7 MILLION shares added to the float that is near 2million. Yall saying it aint that much... you do realize that ends a lot of this stocks ability to halt and go up etc. This will crash pre market, trapping many bag holders who bought above 1.00 which is a majority of you. This is dilution at 7x the float! This is significant in a PHARMA COMPANY we all know how that sht goes, the sector of lots of loss from investors.
$TransCode Therapeutics Inc.(RNAZ)$ the stock was trading over 2 dollars and they come out and do an offering at .51 cents. the management and board should all be firedASAP and this is why I stopped buying penny stocks years ago, to everyone who lost money in this stay away from bio penny stocks, this is always the result.
TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.
08-14
Quarterly Report
Form 10-Q - Quarterly report [Sections 13 or 15(d)]